A phase II study of pomegranate extract for men with rising prostate-specific antigen following primary therapy.

被引：0
|
作者：
Paller, C. J.
Ye, X.
Wozniak, P.
Gillespie, B.
Sieber, P.
Greengold, R.
Stockton, B.
Hertzman, B.
Efros, M.
Roper, R.
Liker, H.
Carducci, M. A.
机构：
[1] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[2] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[3] Adv Clin, Bannockburn, IL USA
[4] Pom Wonderful, Los Angeles, CA USA
[5] Urol Associates Lancaster Ltd, Lancaster, PA USA
[6] South Orange Cty Med Res Ctr, Laguna Hills, CA USA
[7] Lakeside Urol, St Joseph, MI USA
[8] Urol Grp, Cincinnati, OH USA
[9] Accumed Res Associates, Garden City, NY USA
[10] Urol Enterprises, Marietta, GA USA
[11] Univ Calif Los Angeles, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.4522
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4522
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase I-II Trial of Weekly Bicalutamide in Men with Elevated Prostate-Specific Antigen and Negative Prostate Biopsies
    Zanardi, Silvia
    Puntoni, Matteo
    Maffezzini, Massimo
    Bandelloni, Roberto
    Mori, Marco
    Argusti, Alessandra
    Campodonico, Fabio
    Turbino, Laura
    Branchi, Daniela
    Montironi, Rodolfo
    Decensi, Andrea
    CANCER PREVENTION RESEARCH, 2009, 2 (04) : 377 - 384
  • [32] Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy
    Pendleton, John M.
    Tan, Winston W.
    Anai, Satoshi
    Chang, Myron
    Hou, Wei
    Shiverick, Kathleen T.
    Rosser, Charles J.
    BMC CANCER, 2008, 8 (1)
  • [33] Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy
    John M Pendleton
    Winston W Tan
    Satoshi Anai
    Myron Chang
    Wei Hou
    Kathleen T Shiverick
    Charles J Rosser
    BMC Cancer, 8
  • [34] Clinical protocol: Phase I study of an adenovirus/prostate-specific antigen vaccine in men with metastatic prostate cancer
    Lubaroff, DM
    Konety, B
    Link, BK
    Ratliff, TL
    Madsen, T
    Shannon, M
    Ecklund, D
    Williams, RD
    HUMAN GENE THERAPY, 2006, 17 (02) : 220 - 229
  • [35] Psychosocial Trajectories of Men Monitoring Prostate-Specific Antigen Levels Following Surgery for Prostate Cancer
    Bailey, Donald E., Jr.
    Kazer, Meredith Wallace
    Polascik, Thomas J.
    Robertson, Cary
    ONCOLOGY NURSING FORUM, 2014, 41 (04) : 361 - 388
  • [36] Prostate-specific antigen bounce following stereotactic body radiation therapy for prostate cancer
    Vu, Charles C.
    Haas, Jonathan A.
    Katz, Aaron E.
    Witten, Matthew R.
    FRONTIERS IN ONCOLOGY, 2014, 4
  • [37] Late toxicity and early prostate-specific antigen outcome following salvage prostate brachytherapy for select patients following primary radiation therapy
    Suh, W
    Loffredo, MJ
    Schultz, D
    Cormack, RA
    Tempany, CM
    Beard, CJ
    Hurwitz, MD
    Albert, M
    D'Amico, AV
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (02): : S290 - S290
  • [38] Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy
    Coward, Robert M.
    Simhan, Jay
    Carson, Culley C., III
    BJU INTERNATIONAL, 2009, 103 (09) : 1179 - 1183
  • [39] Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer
    Hussain, A
    Dawson, N
    Amin, P
    Engstrom, C
    Dorsey, B
    Siegel, E
    Guo, CF
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (12) : 2789 - 2796
  • [40] A diet, physical activity, and stress reduction intervention in men with rising prostate-specific antigen after treatment for prostate cancer
    Hebert, James R.
    Hurley, Thomas G.
    Harmon, Brook E.
    Heiney, Sue
    Hebert, Christine J.
    Steck, Susan E.
    CANCER EPIDEMIOLOGY, 2012, 36 (02) : E128 - E136
12345